Plenary Session - COVID-19: Understanding the Path Forward for Mesenchymal Stromal Cell Therapies
|
|
|
|
|
|
|
MSC Session - MSC-Derived EVs: Cell Therapy without Cells
|
|
|
|
|
|
|
Commercialization Session - Allogeneic Therapies - What Really is a Healthy Donor?
|
|
|
|
|
|
|
MSC Session - Debating MSC Tissue Sources: Biological and Manufacturing Considerations
|
|
|
|
|
|
|
Commercialization Session - Naming Cell & Gene Therapies – Harmonizing with INN Nomenclature and Regulatory Impact – A Joint ISCT – WHO Session
|
|
|
|
|
|
|
Regulatory Session - The Path to a Biologics License Application (BLA)
|
|
|
|
|
|
|
Presidential Plenary - Integrating Science, Regulatory Oversight, and Commercialization for the New Wave of Cell and Gene Therapies
|
|
|
|
|
|
|
MSC Session - Understanding Regulatory Requirements for Potency Assays
|
|
|
|
|
|
|
Commercialization Session - The Economic Impact on Healthcare and the Future of Advanced Cell & Gene Therapy
|
|
|
|
|
|
|
MSC Session - Lessons & Recommendations for Clinical Trials of MSCs for Musculoskeletal Diseases in 2021
|
|
|
|
|
|
|
Commercialization Session - Advancing the Translational Process through Automation & Equipment that Deliver Successful Scale Up/ Out in Cell Therapies
|
|
|
|
|
|
|
Regulatory Session - Phishing for Cell Therapies – Therapeutic Deception
|
|
|
|
|
|
|